These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 24077346)
21. Divergence of P53, PTEN, PI3K, Akt and mTOR expression in tonsillar cancer. Chun SH; Jung CK; Won HS; Kang JH; Kim YS; Kim MS Head Neck; 2015 May; 37(5):636-43. PubMed ID: 24616007 [TBL] [Abstract][Full Text] [Related]
22. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Adamo B; Deal AM; Burrows E; Geradts J; Hamilton E; Blackwell KL; Livasy C; Fritchie K; Prat A; Harrell JC; Ewend MG; Carey LA; Miller CR; Anders CK Breast Cancer Res; 2011; 13(6):R125. PubMed ID: 22132754 [TBL] [Abstract][Full Text] [Related]
23. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453 [TBL] [Abstract][Full Text] [Related]
24. PTEN, more than the AKT pathway. Blanco-Aparicio C; Renner O; Leal JF; Carnero A Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655 [TBL] [Abstract][Full Text] [Related]
25. SPAG6 promotes cell proliferation and inhibits apoptosis through the PTEN/PI3K/AKT pathway in Burkitt lymphoma. Zhang R; Zhu H; Yuan Y; Wang Y; Tian Z Oncol Rep; 2020 Nov; 44(5):2021-2030. PubMed ID: 33000212 [TBL] [Abstract][Full Text] [Related]
26. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324 [TBL] [Abstract][Full Text] [Related]
27. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Fang J; Ding M; Yang L; Liu LZ; Jiang BH Cell Signal; 2007 Dec; 19(12):2487-97. PubMed ID: 17826033 [TBL] [Abstract][Full Text] [Related]
28. Chromosome 20q13.2 ZNF217 locus amplification correlates with decreased E-cadherin expression in ovarian clear cell carcinoma with PI3K-Akt pathway alterations. Huang HN; Huang WC; Lin CH; Chiang YC; Huang HY; Kuo KT Hum Pathol; 2014 Nov; 45(11):2318-25. PubMed ID: 25281027 [TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma. Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889 [TBL] [Abstract][Full Text] [Related]
30. A novel RON splice variant lacking exon 2 activates the PI3K/AKT pathway via PTEN phosphorylation in colorectal carcinoma cells. Ling Y; Kuang Y; Chen LL; Lao WF; Zhu YR; Wang LQ; Wang D Oncotarget; 2017 Jun; 8(24):39101-39116. PubMed ID: 28388571 [TBL] [Abstract][Full Text] [Related]
31. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma]. Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203 [TBL] [Abstract][Full Text] [Related]
32. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss. Mori N; Kyo S; Sakaguchi J; Mizumoto Y; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M Cancer Sci; 2007 Dec; 98(12):1881-8. PubMed ID: 17924977 [TBL] [Abstract][Full Text] [Related]
33. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: is PTEN loss predictor of local recurrence? Colakoglu T; Yildirim S; Kayaselcuk F; Nursal TZ; Ezer A; Noyan T; Karakayali H; Haberal M Am J Surg; 2008 Jun; 195(6):719-25. PubMed ID: 18440486 [TBL] [Abstract][Full Text] [Related]
34. Gene alterations in the PI3K/PTEN/AKT pathway as a mechanism of drug-resistance (review). Hafsi S; Pezzino FM; Candido S; Ligresti G; Spandidos DA; Soua Z; McCubrey JA; Travali S; Libra M Int J Oncol; 2012 Mar; 40(3):639-44. PubMed ID: 22200790 [TBL] [Abstract][Full Text] [Related]
35. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line. Lee S; Choi EJ; Jin C; Kim DH Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433 [TBL] [Abstract][Full Text] [Related]
36. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633 [TBL] [Abstract][Full Text] [Related]
37. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. López-Knowles E; O'Toole SA; McNeil CM; Millar EK; Qiu MR; Crea P; Daly RJ; Musgrove EA; Sutherland RL Int J Cancer; 2010 Mar; 126(5):1121-31. PubMed ID: 19685490 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817 [TBL] [Abstract][Full Text] [Related]
39. ZEB1 serves as an oncogene in acute myeloid leukaemia via regulating the PTEN/PI3K/AKT signalling pathway by combining with P53. Li L; Feng Y; Hu S; Du Y; Xu X; Zhang M; Peng X; Chen F J Cell Mol Med; 2021 Jun; 25(11):5295-5304. PubMed ID: 33960640 [TBL] [Abstract][Full Text] [Related]
40. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Mueller S; Phillips J; Onar-Thomas A; Romero E; Zheng S; Wiencke JK; McBride SM; Cowdrey C; Prados MD; Weiss WA; Berger MS; Gupta N; Haas-Kogan DA Neuro Oncol; 2012 Sep; 14(9):1146-52. PubMed ID: 22753230 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]